Cargando…

Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy

Detalles Bibliográficos
Autores principales:	Chu, Tianqing, Yuan, Jie, Lu, Jun, Nie, Wei, Zhong, Runbo, Zhang, Bo, Zhang, Wei, Shi, Chunlei, Qian, Jialin, Zhang, Yanwei, Zhang, Xueyan, Teng, Jiajun, Gao, Zhiqiang, Lou, Yuqing, Li, Jiaqi, Qiang, Huiping, Zhang, Chao, Li, Jin, Xia, Xuefeng, Zhong, Hua, Han, Baohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230154/ https://www.ncbi.nlm.nih.gov/pubmed/37254636 http://dx.doi.org/10.1002/ctm2.1277

Ejemplares similares

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
por: Chu, Tianqing, et al.
Publicado: (2022)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?
por: Lou, Yuqing, et al.
Publicado: (2020)

Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery
por: Lu, Jun, et al.
Publicado: (2023)

Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2019)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
por: Zhang, Bo, et al.
Publicado: (2022)

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update
por: Lu, Jun, et al.
Publicado: (2022)

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
por: Xiong, Anning, et al.
Publicado: (2023)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
por: Yu, Lian, et al.
Publicado: (2022)

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy
por: Shen, Yinchen, et al.
Publicado: (2020)

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
por: Zhang, Yanwei, et al.
Publicado: (2020)

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527
por: Li, Changhui, et al.
Publicado: (2021)

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
por: Wei, Wei, et al.
Publicado: (2022)

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
por: Zheng, Liang, et al.
Publicado: (2023)

Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases
por: Qiao, Rong, et al.
Publicado: (2017)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
por: Li, Changhui, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma
por: Hu, Minjuan, et al.
Publicado: (2020)

Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study
por: Qiang, Huiping, et al.
Publicado: (2022)

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients
por: Lu, Jun, et al.
Publicado: (2021)

Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
por: Lu, Jun, et al.
Publicado: (2022)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
por: Qiao, Rong, et al.
Publicado: (2019)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report
por: Gui, Lin, et al.
Publicado: (2021)

Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
por: Lou, Yuqing, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study
por: Chang, Qing, et al.
Publicado: (2021)

Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report
por: Fu, Lingli, et al.
Publicado: (2021)

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer
por: Chen, Dongfang, et al.
Publicado: (2020)

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
por: Liu, Zichang, et al.
Publicado: (2023)

A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab
por: Shen, Yinchen, et al.
Publicado: (2022)

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022)

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells
por: Zhang, Xueyan, et al.
Publicado: (2018)

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line
por: Lu, Jun, et al.
Publicado: (2019)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy
por: Fan, Peng, et al.
Publicado: (2022)

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2021)

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
por: Lu, Jun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_26qgm87f0jo1jpk5t5n2a6ffa1